Inicio › Cáncer de endometrio › Massachusetts › Boston
Ensayos clínicos de Cáncer de endometrio en Boston, MA
50 estudios para Cáncer de endometrio buscan participantes en centros de Boston y alrededores (a unos 30 millas). Abra un estudio para ver quién puede participar y cómo contactar con el equipo.
Texto oficial del estudio (inglés)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
ReclutandoFase 2
- Tufts Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
ReclutandoFase 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Distance-Based Exercise to Preserve Function and Prevent Disability
Reclutando
- Dana-Farber Cancer Institute, Boston
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
ReclutandoFase 3
- Dana-Farber Cancer Institute, Boston
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
ReclutandoFase 2
- Dana-Farber Cancer Institute - Oncology Department, Boston
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
ReclutandoFase 1
- Dana Farber Cancer Institute, Boston
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
ReclutandoFase 1
- Research Site, Boston
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
ReclutandoFase 1/2
- Massachusetts General Hospital, Boston
- Dana Farber / Harvard Cancer Center, Boston
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
ReclutandoFase 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute Brookline Avenue, Boston
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
ReclutandoFase 2
- Massachusetts General Hospital Cancer Center, Boston
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
ReclutandoFase 1/2
- Dana Farber Cancer Institute, Boston
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
ReclutandoFase 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
ReclutandoFase 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
ReclutandoFase 3
- Tufts Medical Center ( Site 6052), Boston
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
ReclutandoFase 1/2
- Massachusetts General Hospital, Boston
ALPINE: Maintenance Letrozole/Abemaciclib
ReclutandoFase 2
- Beth Israel Deaconess Medical Center, Boston
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
ReclutandoFase 1/2
- Research Site, Boston
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
ReclutandoFase 1
- Dana Farber Cancer Institute, Boston
Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.
ReclutandoFase 1
- Dana-Farber Cancer Institute, Boston
A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
ReclutandoFase 1
- Dana-Farber Cancer Institute, Boston
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
ReclutandoFase 3
- Research Site, Boston
Concurrent Laparoscopic Hysterectomy and Weight Loss Surgery in Obese Patients With Endometrial Carcinoma or Endometrial Intraepithelial Neoplasia
Reclutando
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
ReclutandoFase 1
- Mass General Cancer Center, Boston
A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
ReclutandoFase 1
- Dana-Farber Cancer Institute, Boston
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
ReclutandoFase 1/2
- Dana-Farber Cancer Institute, Boston
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
ReclutandoFase 1
- Dana Farber Cancer Institute, Boston
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
ReclutandoFase 1/2
- Research Site, Boston
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
ReclutandoFase 2
- Dana Farber Cancer Institute, Boston
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
ReclutandoFase 1/2
- Massachusetts General Hospital, Boston
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
ReclutandoFase 1
- Normunity Investigational Site, Boston
- Normunity Investigational Site, Boston
FOG-001 in Locally Advanced or Metastatic Solid Tumors
ReclutandoFase 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Study of PHST001 in Advanced Solid Tumors
ReclutandoFase 1
- Dana Farber Cancer Institute, Boston
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
ReclutandoFase 1/2
- Massachusetts General Hospital Cancer Center, Boston
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
ReclutandoFase 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
ReclutandoFase 1/2
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
ReclutandoFase 1
- Mass General Brigham Cancer Institute at Massachusetts General Hospital, Boston
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
ReclutandoFase 1/2
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
ReclutandoFase 1/2
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
A Study of LY4175408 in Participants With Advanced Cancer
ReclutandoFase 1
- Massachusetts General Hospital, Boston
RESOLVE: Abemaciclib + Letrozole +/- Metformin or Gedatolisib in Endometrial Cancer
ReclutandoFase 2
- Massachusetts General Hospital Cancer Center, Boston
- Beth Israel Deaconess Medical Center (BIDMC), Boston
- Dana Farber Cancer Institute, Boston
Menstrual Cup for Early Endometrial Cancer Detection in Lynch Syndrome
ReclutandoSe aceptan voluntarios sanos
- Dana-Farber Cancer Institute, Boston
A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
ReclutandoFase 1
- Mass General Brigham Cancer Institute, Boston
- Dana Farber Cancer Institute, Boston
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
ReclutandoFase 1/2
- Massachusetts General Hospital, Boston
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
ReclutandoFase 1/2
- Massachusetts General Hospital, Boston
Exercise as a Preventive Agent to Combat Immobility in Patients With Ovarian or Endometrial Cancers Receiving Chemotherapy
Reclutando
- Dana Farber Cancer Institute, Boston
Avelumab and M1774 in ARID1A-mutated Endometrial Cancer
ReclutandoFase 2
- Dana-Farber Cancer Institute, Boston
- Brigham and Women's Hospital, Boston
Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin
ReclutandoFase 2
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
ReclutandoFase 1/2
- Dana Farber Cancer Institute, Boston
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
ReclutandoFase 1/2
- Massachusetts General Hospital, Boston
Comprehensive Outcomes for After Cancer Health
ReclutandoSe aceptan voluntarios sanos
- Dana Farber Cancer Institute, Boston
Ensayos de Cáncer de endometrio en otras ciudades
- Houston, TX68 estudios
- New York City, NY52 estudios
- Arlington, VA39 estudios
- Nashville, TN38 estudios
- Los Angeles, CA34 estudios
- St. Louis, MO29 estudios
- Philadelphia, PA28 estudios
- San Antonio, TX27 estudios
- Chicago, IL25 estudios
- Columbus, OH25 estudios
- Queens, NY25 estudios
- Oklahoma City, OK25 estudios
Otros estudios en Boston
- Cáncer de seno111 estudios
- Cáncer de pulmón de células no pequeñas90 estudios
- Cáncer (todos los tipos)86 estudios
- Cáncer del colon y del recto63 estudios
- Cáncer metastásico63 estudios
- Cáncer de pulmón62 estudios
- Cáncer de ovario61 estudios
- Cáncer de próstata59 estudios
- Depresión52 estudios
- Fallo cardíaco44 estudios
- Leucemia mielógena aguda44 estudios
- Cáncer de páncreas43 estudios
De ClinicalTrials.gov, datos obtenidos el 5 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.